The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease
Open accessAbstract
Hypercholesterolemia is one of the major causes of coronary heart disease (CHD). The genes encoding the low-density lipoprotein receptor and its ligand apolipoprotein B, have been the two genes classically implicated in autosomal dominant hypercholesterolemia (ADH). Our discovery in 2003 of the first mutations of the proprotein convertase subtilisin kexin 9 gene (PCSK9) causing ADH shed light on an unknown actor in cholesterol metabolism that since then has been extensively investigated. Several PCSK9 variants have been identified, some of them are gain-of-function mutations causing hypercholesterolemia by a reduction of low-density lipoprotein (LDL) receptor levels; while others are loss-of-function variants associated with a reduction of LDL-cholesterol (LDL-C) levels and a decreased risk of CHD. In this review, we focus on reported variants, and their biological, clinical, and functional relevance. We also highlight the spectrum of hypercholesterolemia or hypobetalipoproteinemia phenotypes that are already associated with mutations in PCSK9. Finally, we present future prospects concerning this therapeutic target that might constitute a new approach to reduce cholesterol levels and CHD, and enhance the effectiveness of other lipid-lowering drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lusis, A. J. (2000) · Nature · doi:10.1038/35025203 · Cited by 4,839
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Self-citationFat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders
Fredrickson, D. S., Levy, R. I., & Lees, R. S. (1967) · New England Journal of Medicine · doi:10.1056/nejm196701052760107 · Cited by 1,910
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11041 · Cited by 1,134
Zhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702027200 · Cited by 788
Fat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders
Fredrickson, D. S., Levy, R. I., & Lees, R. S. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702022760507 · Cited by 747
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y.-A., & Horton, J. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501652102 · Cited by 679
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 632
Garcia, C. K., Wilund, K., Arca, M., Zuliani, G., Fellin, R., Maioli, M., Calandra, S., Bertolini, S., Cossu, F., Grishin, N., et al. (2001) · Science · doi:10.1126/science.1060458 · Cited by 624
Molecular biology of PCSK9: its role in LDL metabolism
HORTON, J., COHEN, J., & HOBBS, H. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.12.008 · Cited by 621
Maxwell, K. N., & Breslow, J. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402133101 · Cited by 613
NARC-1/PCSK9 and Its Natural Mutants
Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M.-C., Hamelin, J., Varret, M., Allard, D., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409699200 · Cited by 587
Self-citationDubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N. G., Bernier, L., & Prat, A. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000134621.14315.43 · Cited by 570
Victor, R. G., Haley, R. W., Willett, D. L., Peshock, R. M., Vaeth, P. C., Leonard, D., Basit, M., Cooper, R. S., Iannacchione, V. G., Visscher, W. A., et al. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.02.058 · Cited by 527
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517
Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding.
Innerarity, T. L., Weisgraber, K. H., Arnold, K. S., Mahley, R. W., Krauss, R. M., Vega, G. L., & Grundy, S. M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6919 · Cited by 491
Park, S. W., Moon, Y.-A., & Horton, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410077200 · Cited by 452
Maxwell, K. N., Fisher, E. A., & Breslow, J. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409736102 · Cited by 415
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
Cunningham, D., Danley, D. E., Geoghegan, K. F., Griffor, M. C., Hawkins, J. L., Subashi, T. A., Varghese, A. H., Ammirati, M. J., Culp, J. S., Hoth, L. R., et al. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1235 · Cited by 409
Molecular basis for LDL receptor recognition by PCSK9
Kwon, H. J., Lagace, T. A., McNutt, M. C., Horton, J. D., & Deisenhofer, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712064105 · Cited by 389
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Hooper, A. J., Marais, A. D., Tanyanyiwa, D. M., & Burnett, J. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.039 · Cited by 364
Maxwell, K. N., Soccio, R. E., Duncan, E. M., Sehayek, E., & Breslow, J. L. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300203-jlr200 · Cited by 329
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
Timms, K. M., Wagner, S., Samuels, M. E., Forbey, K., Goldfine, H., Jammulapati, S., Skolnick, M. H., Hopkins, P. N., Hunt, S. C., & Shattuck, D. M. (2004) · Human Genetics · doi:10.1007/s00439-003-1071-9 · Cited by 321
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Careskey, H. E., Davis, R. A., Alborn, W. E., Troutt, J. S., Cao, G., & Konrad, R. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700437-jlr200 · Cited by 313
Costet, P., Cariou, B., Lambert, G., Lalanne, F., Lardeux, B., Jarnoux, A.-L., Grefhorst, A., Staels, B., & Krempf, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508582200 · Cited by 304
Graham, M. J., Lemonidis, K. M., Whipple, C. P., Subramaniam, A., Monia, B. P., Crooke, S. T., & Crooke, R. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.c600025-jlr200 · Cited by 293
The inheritance of essential familial hypercholesterolemia
Khachadurian, A. K. (1964) · The American Journal of Medicine · doi:10.1016/0002-9343(64)90196-2 · Cited by 280
The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A
Benjannet, S., Rhainds, D., Hamelin, J., Nassoury, N., & Seidah, N. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606495200 · Cited by 263
Effect of mutations in the PCSK9 gene on the cell surface LDL receptors
Cameron, J., Holla, Ø. L., Ranheim, T., Kulseth, M. A., Berge, K. E., & Leren, T. P. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl077 · Cited by 258
Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia
Leren, T. (2004) · Clinical Genetics · doi:10.1111/j.0009-9163.2004.0238.x · Cited by 255
The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
Piper, D. E., Jackson, S., Liu, Q., Romanow, W. G., Shetterly, S., Thibault, S. T., Shan, B., & Walker, N. P. C. (2007) · Structure · doi:10.1016/j.str.2007.04.004 · Cited by 251
McNutt, M. C., Lagace, T. A., & Horton, J. D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.c700095200 · Cited by 251
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
Nassoury, N., Blasiole, D. A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., & Seidah, N. G. (2007) · Traffic · doi:10.1111/j.1600-0854.2007.00562.x · Cited by 248
Berge, K. E., Ose, L., & Leren, T. P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000204337.81286.1c · Cited by 236
Berberine decreases PCSK9 expression in HepG2 cells
Cameron, J., Ranheim, T., Kulseth, M. A., Leren, T. P., & Berge, K. E. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.02.004 · Cited by 233
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
Mayne, J., Dewpura, T., Raymond, A., Cousins, M., Chaplin, A., Lahey, K. A., LaHaye, S. A., Mbikay, M., Ooi, T., & Chrétien, M. (2008) · Lipids in Health and Disease · doi:10.1186/1476-511x-7-22 · Cited by 217
RISK FACTORS FOR CORONARY HEART DISEASE IN ADULT FEMALE TWINS
AUSTIN, M. A., KING, M.-C., BAWOL, R. D., HULLEY, S. B., & FRIEDMAN, G. D. (1987) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114531 · Cited by 207
Lowering LDL—not only how low, but how long?
Brown, M. S., & Goldstein, J. L. (2006) · Science · doi:10.1126/science.1125884 · Cited by 204
Precursor convertases in the secretory pathway, cytosol and extracellular milieu
Seidah, N. G., & Prat, A. (2002) · Essays in Biochemistry · doi:10.1042/bse0380079 · Cited by 203
Novel mutations of thePCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia
Allard, D., Amsellem, S., Abifadel, M., Trillard, M., Devillers, M., Luc, G., Krempf, M., Reznik, Y., Girardet, J.-P., Fredenrich, A., et al. (2005) · Human Mutation · doi:10.1002/humu.9383 · Cited by 187
Self-citationOuguerram, K., Chetiveaux, M., Zair, Y., Costet, P., Abifadel, M., Varret, M., Boileau, C., Magot, T., & Krempf, M. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000133684.77013.88 · Cited by 185
Self-citationA PCSK9 Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction
Kathiresan, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0707445 · Cited by 183
Plasma PCSK9 preferentially reduces liver LDL receptors in mice
Grefhorst, A., McNutt, M. C., Lagace, T. A., & Horton, J. D. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800027-jlr200 · Cited by 183
Naoumova, R. P., Tosi, I., Patel, D., Neuwirth, C., Horswell, S. D., Marais, A. D., van Heyningen, C., & Soutar, A. K. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000190668.94752.ab · Cited by 182
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation
Fisher, T. S., Surdo, P. L., Pandit, S., Mattu, M., Santoro, J. C., Wisniewski, D., Cummings, R. T., Calzetta, A., Cubbon, R. M., Fischer, P. A., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701634200 · Cited by 181
A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Varret, M., Rabès, J.-P., Saint-Jore, B., Cenarro, A., Marinoni, J.-C., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302370 · Cited by 175
Self-citationLambert, G., Ancellin, N., Charlton, F., Comas, D., Pilot, J., Keech, A., Patel, S., Sullivan, D. R., Cohn, J. S., Rye, K.-A., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.099747 · Cited by 166
Hampton, E. N., Knuth, M. W., Li, J., Harris, J. L., Lesley, S. A., & Spraggon, G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703402104 · Cited by 165
Alborn, W. E., Cao, G., Careskey, H. E., Qian, Y.-W., Subramaniam, D. R., Davies, J., Conner, E. M., & Konrad, R. J. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.091280 · Cited by 163
Chen, S. N., Ballantyne, C. M., Gotto, A. M., Tan, Y., Willerson, J. T., & Marian, A. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.051 · Cited by 162
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity
Li, J., Tumanut, C., Gavigan, J.-A., Huang, W.-J., Hampton, E. N., Tumanut, R., Suen, K. F., Trauger, J. W., Spraggon, G., Lesley, S. A., et al. (2007) · Biochemical Journal · doi:10.1042/bj20070664 · Cited by 157
Sun, X.-M., Eden, E. R., Tosi, I., Neuwirth, C. K. Y., Wile, D. B., Naoumova, R. P., & Soutar, A. K. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi128 · Cited by 157
Functional characterization of Narc 1, a novel proteinase related to proteinase K
Naureckiene, S., Ma, L., Sreekumar, K. R., Purandare, U., Lo, C. F., Huang, Y., Chiang, L. W., Grenier, J. M., Ozenberger, B. A., Jacobsen, J. S., et al. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.09.011 · Cited by 155
Fasano, T., Cefalu, A. B., Leo, E. D., Noto, D., Pollaccia, D., Bocchi, L., Valenti, V., Bonardi, R., Guardamagna, O., Averna, M. R., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000255311.26383.2f · Cited by 142
Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
Langhi, C., May, C. L., Kourimate, S., Caron, S., Staels, B., Krempf, M., Costet, P., & Cariou, B. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.02.038 · Cited by 128
Hunt, S. C., Hopkins, P. N., Bulka, K., McDermott, M. T., Thorne, T. L., Wardell, B. B., Bowen, B. R., Ballinger, D. G., Skolnick, M. H., & Samuels, M. E. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.4.1089 · Cited by 123
Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system
Poirier, S., Prat, A., Marcinkiewicz, E., Paquin, J., Chitramuthu, B. P., Baranowski, D., Cadieux, B., Bennett, H. P. J., & Seidah, N. G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03928.x · Cited by 121
Lambert, G. C., Jarnoux, A. L., Pineau, T., Pape, O., Chétiveaux, M., LABOISSE, C. L., Krempf, M., & Costet, P. (2006) · Endocrinology · doi:10.1210/en.2006-0098 · Cited by 120
Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity
Fan, D., Yancey, P. G., Qiu, S., Ding, L., Weeber, E. J., Linton, M. F., & Fazio, S. (2008) · Biochemistry · doi:10.1021/bi7016359 · Cited by 116
Biosynthesis and Cellular Trafficking of the Convertase SKI-1/S1P
Elagoz, A., Benjannet, S., Mammarbassi, A., Wickham, L., & Seidah, N. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109011200 · Cited by 113
Schmidt, R. J., Beyer, T. P., Bensch, W. R., Qian, Y., Lin, A., Kowala, M. C., Alborn, W. E., Konrad, R. J., & Cao, G. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.004 · Cited by 110
Pisciotta, L., Oliva, C. P., Cefalu, A. B., Noto, D., Bellocchio, A., Fresa, R., Cantàfora, A., Patel, D., Averna, M. R., Tarugi, P., et al. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.08.015 · Cited by 108
Scartezini, M., Hubbart, C., Whittall, R., Cooper, J. A., Neil, A., & Humphries, S. E. (2007) · Clinical Science · doi:10.1042/cs20070150 · Cited by 106
Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9
Kourimate, S., May, C. L., Langhi, C., Jarnoux, A. L., Ouguerram, K., Zaïr, Y., Nguyen, P., Krempf, M., Cariou, B., & Costet, P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705831200 · Cited by 103
Miyake, Y., Kimura, R., Kokubo, Y., Okayama, A., Tomoike, H., Yamamura, T., & Miyata, T. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.12.035 · Cited by 96
Familial hypercholesterolaemia in Portugal
Bourbon, M., Alves, A. C., Medeiros, A. M., Silva, S. D. R., & Soutar, A. K. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.07.019 · Cited by 90
Dewpura, T., Raymond, A., Hamelin, J., Seidah, N. G., Mbikay, M., Chrétien, M., & Mayne, J. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06495.x · Cited by 87
Homer, V. M., Marais, A. D., Charlton, F., Laurie, A. D., Hurndell, N., Scott, R., Mangili, F., Sullivan, D. R., Barter, P. J., Rye, K.-A., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.07.022 · Cited by 84
Genetic variants in PCSK9 affect the cholesterol level in Japanese
Shioji, K., Mannami, T., Kokubo, Y., Inamoto, N., Takagi, S., Goto, Y., Nonogi, H., & Iwai, N. (2004) · Journal of Human Genetics · doi:10.1007/s10038-003-0114-3 · Cited by 81
Plasma PCSK9 levels correlate with cholesterol in men but not in women.
Mayne, J., Raymond, A., Chaplin, A., Cousins, M., Kaefer, N., Gyamera-Acheampong, C., Seidah, N. G., Mbikay, M., Chrétien, M., & Ooi, T. C. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.07.029 · Cited by 81
Familial hypercholesterolemia: pathogenesis of a receptor disease.
Goldstein, J. L., & Brown (1978) · PubMed · Cited by 80
Evans, D., & Beil, F. U. (2006) · BMC Medical Genetics · doi:10.1186/1471-2350-7-66 · Cited by 80
Abboud, S., Karhunen, P. J., Lütjohann, D., Goebeler, S., Luoto, T., Friedrichs, S., Lehtimaki, T., Pandolfo, M., & Laaksonen, R. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001043 · Cited by 77
Yue, P., Averna, M. R., Lin, X., & Schonfeld, G. (2006) · Human Mutation · doi:10.1002/humu.20316 · Cited by 75
Characterization of novel mutations in the catalytic domain of the PCSK9 gene
Cameron, J., Holla, Ø. L., Laerdahl, J. K., Kulseth, M. A., Ranheim, T., Rognes, T., Berge, K. E., & Leren, T. P. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01915.x · Cited by 71
Holla, Ø. L., Cameron, J., Berge, K. E., Ranheim, T., & Leren, T. P. (2007) · BMC Cell Biology · doi:10.1186/1471-2121-8-9 · Cited by 70
Pseudohomozygous type II hyperlipoproteinemia
Morganroth, J., Levy, R. I., McMahon, A. E., et al. (1974) · The Journal of Pediatrics · doi:10.1016/s0022-3476(74)80506-8 · Cited by 53
Folsom, A. R., Peacock, J. M., & Boerwinkle, E. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0502 · Cited by 36
Abifadel, M., Rabès, J., Boileau, C., & Varret, M. (2007) · Annales d Endocrinologie · doi:10.1016/j.ando.2007.02.002 · Cited by 25
Self-citationMbikay, M., Mayne, J., Seidah, N. G., & Chrétien, M. (2007) · Medical Hypotheses · doi:10.1016/j.mehy.2007.03.018 · Cited by 25
Saint-Jore, B., Varret, M., Dachet, C., Rabès, J., Devillers, M., Erlich, D., Blanchard, P., Krempf, M., Mathé, D., Chanu, B., et al. (2000) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200516 · Cited by 18
Self-citationPCSK9, du gène à la protéine : un nouvel acteur dans l’homéostasie du cholestérol
Abifadel, M., Rabès, J., Boileau, C., & Varret, M. (2006) · médecine/sciences · doi:10.1051/medsci/20062211916 · Cited by 10
Self-citation
Cited by
The biology and therapeutic targeting of the proprotein convertases
Seidah, N. G., & Prat, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3699 · Cited by 759
Seidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596
Testing for an Unusual Distribution of Rare Variants
Neale, B. M., Rivas, M. A., Voight, B. F., Altshuler, D., Devlin, B., Orho-Melander, M., Kathiresan, S., Purcell, S. M., Roeder, K., & Daly, M. J. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001322 · Cited by 580
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
Lagace, T. A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000114 · Cited by 372
Diagnosis and treatment of familial hypercholesterolaemia
Hovingh, G. K., Davidson, M. H., Kastelein, J. J. P., & O'Connor, A. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht015 · Cited by 256
Metadata
- Authors
- Abifadel, M., Rabès, J.-P., Devillers, M., Munnich, A., Erlich, D., Junien, C., Varret, M., & Boileau, C.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2009-02-03
- Volume
- 30
- Issue
- 4
- Pages
- 520-529
- ISSN
- 1059-7794 (ISSN-L)
- OpenAlex
- W2028682402
- Cited by
- 256
- References
- 87
- FWCI
- 19.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.